Almujtama Alraida Medical Co.

9592.SRSAUHealthcare● Active

$24.60

+$1.10(+4.68%)

Market Cap$233700000

P/E Ratio—

52W High$33.5

52W Low$22

Avg Volume3K

Open$24.60

Beta0.15

Free Cash Flow Financials Revenue

Almujtama Alraida Medical Co. (9592.SR) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

9592.SR · free cash flow · updated Jun 15, 2026

Core FCF metrics

9592.SR · FCF · TTM · margin & CAGR

Free cash flow was $23.2M for FY2024 (fiscal year ending 2024-12-31), down 16.6% year-over-year The FCF margin was 5.4%.

FY2024 Free Cash Flow$23.2M▼ -16.6% YoY

Trailing 12M (TTM)$50.9Mtrailing 4 quarters sum

FCF Margin5.4%$23.2M ÷ revenue

3-Year CAGR+32.5%FY2021 → FY2024

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 15, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

9592.SR · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2024Latest$51.4M(28M)$23.2M▼ 16.6%5.4%

FY2023$68.1M(40M)$27.7M▲ +2766.3%6.8%

FY2022$18.5M(20M)−$1.0M▼ 110.5%-0.3%

FY2021$17.3M(7M)$9.9M—3.3%

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

9592.SR · P/FCF · FCF yield · FCF per share

Almujtama Alraida Medical Co. (9592.SR) trades at a FCF yield of 4.50% and a price-to-free-cash-flow ratio of 4.6x. FCF per share stands at $5.34, calculated using trailing twelve-month FCF divided by basic weighted-average shares outstanding.

FCF Yield (TTM)

4.50%

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

$5.34

TTM FCF ÷ Shares Outstanding

Price / FCF

x4.6

Share Price ÷ FCF per Share

EV / FCF (TTM)

x39.0

Enterprise Value basis

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2024 · 2024-12-31

Cash flow statement summary

9592.SR · cash flow statement · operating / investing / financing

For FY2024, Almujtama Alraida Medical Co. generated $51.4M in operating cash flow and spent 28M in capital expenditures, yielding $23.2M in free cash flow.

Operating Activities

+$51.4M

Cash from core business operations

2024-12-31

Investing Activities

−$28.0M

CapEx, acquisitions & investments

2024-12-31

Financing Activities

−$34.2M

Buybacks, dividends & debt

2024-12-31

FCF FormulaOperating CF ($51.4M) − |CapEx| (28M) = FCF ($23.2M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

9592.SR vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Almujtama Alraida Medical Co.YOU

9592.SR

$23.2M-16.6%5.1%

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Almujtama Alraida Medical Co. (9592.SR) reported free cash flow of $23.2M for FY2024 (fiscal year ending 2024-12-31), down 16.6% year-over-year. The FCF margin was 5.4%.

Based on available data, Almujtama Alraida Medical Co. has maintained positive free cash flow for at least 3 fiscal year(s). FCF peaked at $27.7M in FY2023.

Almujtama Alraida Medical Co.'s FCF yield is 4.50% and price-to-FCF ratio is 4.6x for FY2024, based on the latest available data.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

9592.SR free cash flow · 8 questions

Almujtama Alraida Medical Co. free cash flow was $23.2M for FY2024, down 16.6% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at $50.9M.

9592.SR free cash flow9592.SR FCF9592.SR FCF 20249592.SR free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Almujtama Alraida Medical Co. · Almujtama Alraida Medical Co. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 15, 2026